$CLX · CLOROX CO /DE/
Clorox filed an 8-K announcing the appointment of Fabian Garcia as CEO and Board member, effective January 5, 2027. Garcia succeeds Linda Rendle, who is stepping down for health reasons and will serve as senior advisor through April 2, 2027. Matthew Shattock becomes Independent Chair. Garcia's offer letter details a $100,000 base salary, $2M target annual bonus settled in stock, and a $4.55M long-term incentive award (60% performance share units, 40% RSUs).
- Fabian Garcia appointed CEO effective January 5, 2027; currently Unilever Personal Care president.
- Linda Rendle steps down as CEO and Chair for health reasons; stays as senior advisor through April 2, 2027.
- Matthew Shattock transitions from Lead Independent Director to Independent Chair of the Board.
- Garcia's compensation: $100,000 base salary, $2M target annual bonus, $4.55M target long-term incentive.
- Garcia brings 40+ years at Unilever, Revlon, Colgate-Palmolive, and Procter & Gamble; sits on Wells Fargo board.
Extended-hours trading shows CLX at $87.87, up +1.19% vs the regular close of $86.84, suggesting a mildly positive initial reception to the CEO announcement.
A planned CEO transition at a $10.5B consumer staples giant with an external CPG veteran signals the board's intent to strengthen execution after a period of disruption.
Garcia's appointment brings deep CPG bench strength from Unilever, Colgate-Palmolive, and P&G. His Revlon CEO stint (2016–2018) included a challenging turnaround; Clorox investors will scrutinize whether that experience translates to the household-products space.
CEO transitions carry execution risk, particularly with an external hire. Garcia's $100K base salary is unusually low for a $10.5B market-cap company — the bulk of compensation is performance-linked equity, which could incentivize short-term risk-taking. Rendle's departure for health reasons was flagged in May, so this is a planned succession, not a surprise.